Please go to the PowerPak homepage
and select a course.
Managed Care and Specialty Pharmacist Perspectives in Hepatitis C: A 2016 Update - HCV Treatment Assessment:
Navigating HCV Treatment and Treatment Failure — Case 2
Provided by The University of Tennessee College of Pharmacy, in cooperation with ASiM.
Supported by an educational grant from Merck & Co Inc.
Chronic hepatitis C virus (HCV) infection is a leading cause of cirrhosis, hepatocellular carcinoma, and liver-related morbidity and mortality. With a current prevalence of approximately 2.7 million patients in the United States, chronic HCV infection represents a major public health burden for patients, providers, and the healthcare system. Over the past several years, the standards of care for patients with chronic HCV infection have evolved to feature all-oral, interferon-free, and sometimes ribavirin-free regimens that incorporate one or more direct acting antiviral agents. Pharmacists play a central role in ensuring the delivery of safe and effective patient care by confirming the optimal choice, dose, and duration of treatment; screening for potential drug-drug interactions; and educating patients about the importance of medication adherence as well as the possibility of treatment-related side-effects. This case-based educational activity features common scenarios encountered in clinical practice, with the goal of highlighting the latest standards of care in HCV patient assessment and individualized treatment selection.
The goal of this activity is to provide pharmacists with the most up-to-date clinical knowledge and strategies for the optimal assessment and management of patients with HCV.
This enduring case activity is designed for pharmacists. No prerequisites required.
The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity. At the conclusion of this activity, the participant should be able to:
- Assess the efficacy and safety of the newest guideline-based treatments for HCV.
- Evaluate emerging treatment paradigms and regimens for HCV.
- Implement pharmacist-driven strategies to enhance adherence to HCV treatment regimens.
CREDIT DESIGNATION STATEMENT
The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this knowledge-based program will provide a statement for 0.5 contact hours of credit (0.05 CEUs) and will be available at the completion of the activity. Successfully completing the activity and receiving credit includes: 1) attending the session; 2) watching, listening to, and participating in the educational activity; 3) completing the self-assessment instrument with a score of at least 70%. CE credit will be submitted to the NABP CE Monitor. UAN: 0064-0000-16-202-H01-P.
NABP e-PROFILE ID NUMBER
Your CE credits will also be submitted electronically to NABP. Pharmacists or pharmacy technicians with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website: http://www.nabp.net/programs/cpe-monitor/cpe-monitor-service. To receive credit for your participation in this course, all pharmacists must include their NABP e-Profile ID number, along with their date and month of birth on the last page of the evaluation form.
Type of Activity: Application
Published: February 15, 2016
Expires: February 15, 2017
Fee Information: There is no fee for this educational activity.
Estimated time to complete activity: 30 minutes
HOW TO EARN CREDIT
Participants must complete the activity as described above in the Credit Designation Statement. To answer the questions, click on your selected choice for each answer then proceed to the next question. We recommend that you print a copy of your answers before you submit them to us. Once completed, click on Submit Post-test at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of CE credit will be made available immediately. Click on View Certificate and print the CE statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the post-test. You will have 2 opportunities to pass the post-test.
FULL DISCLOSURE POLICY AFFECTING CPE ACTIVITIES
As an accredited provider by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of The University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Course Director and Participating Faculty reported the following:
Pamela S. Belperio, PharmD, BCPS, AAHIVE (Course Director)
National Public Health Clinical Pharmacist
VA Office of Public Health/Population Health
Department of Veterans Affairs
Los Angeles, California
Dr Belperio reports having no relevant financial or advisory relationships with corporate organizations related to this activity.
Jason P. Smith, PharmD
Department of Pharmacy
Greater Los Angeles Veterans Affairs
West Los Angeles VA Medical Center
Los Angeles, California
Dr Smith reports having no relevant financial or advisory relationships with corporate organizations related to this activity.
OFF-LABEL PRODUCT DISCUSSION
In accordance with ACPE Criteria for Quality, the audience is advised that authors in this CPE activity may include reference(s) to unlabeled, unapproved, or investigational uses of therapeutic agents or biomedical devices. The authors will inform the reader of when they discuss or reference an unapproved, unlabeled, or investigational use of therapeutic agent or biomedical device.
The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of The University of Tennessee College of Pharmacy name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.
A participant, sponsor, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity sponsored or cosponsored by The University of Tennessee College of Pharmacy may contact the Associate Dean for Continuing Education in writing at firstname.lastname@example.org. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.
The following is an interactive case simulation designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of 3 sections: an unaccredited pre-test, an interactive case study, and a CPE post-test, and evaluation. All 3 sections must be completed to receive CPE credit. A statement of credit will be available online immediately following successful completion of the activity.
REQUIRED COMPUTER HARDWARE/SOFTWARE
Please ensure the computer you plan to use meets the following minimum requirements:
- Operating System: Windows 98 or higher & Macintosh 2.2 or higher
- Internet Browser (Mac &/Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
- Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible.
- Peripherals: Computer speakers or headphones
- Monitor Screen Resolution: 320 x 480 or higher
- Media Viewing Requirements: Adobe Reader, Microsoft Power Point, Flash Player & HTML5
TABLE OF CONTENTS
Managed Care and Specialty Pharmacist Perspectives in Hepatitis C:
A 2016 Update - HCV Treatment Assessment: Navigating HCV Treatment and Treatment Failure – Case 2
Pamela S. Belperio, PharmD, BCPS, AAHIVE, and Jason P. Smith, PharmD